Localized Steroid-Releasing Technology

Intersect ENT’s core technology is its bioabsorbable, sustained drug release platform. This advancement in ENT surgery improves patient care and is a cost effective option for preventing the need for postoperative interventions.1

PROPEL and PROPEL Mini Chronic Sinusitis Implants
propel logo

Opens. Delivers. Maintains.

PROPEL sinus implants are the first of a new category of products offering localized, controlled drug delivery directly to the sinus tissue.2

Inserted to maintain the surgical opening, the springlike implant is placed in the sinus cavity following surgery and expands to prop open the sinus and gradually deliver an advanced corticosteroid with anti-inflammatory properties directly to the sinus lining as the implant dissolves.

propel logo

PROPEL improves post-ethmoid sinus surgery outcomes compared to spacing alone, reducing the need for additional surgical procedures and oral steroids.2

Learn About PROPEL

propel mini logo

Similar in design to PROPEL, and with the same drug dose, PROPEL Mini is a smaller sinus implant ideal for patients with smaller nasal anatomy, less extensive surgery, or those requiring frontal sinus treatment.

Learn About PROPEL mini

Continuing the Innovation

We are working on new technologies to provide localized drug delivery to even more patients.

Learn More

1Rudmik L and Smith TL. Economic Evaluation of a Steroid-Eluting Sinus Implant following Endoscopic Sinus Surgery for Chronic Rhinosinusitis. Otolaryngol Head Neck Surg. 2014 May 5; 151(2):359-366.
2Han JK, Marple BF, Smith TL, et al. Int Forum Allergy Rhinol. 2012; 2:271-279.

The PROPEL sinus implant is intended for use following ethmoid sinus surgery to maintain patency. PROPEL Mini is intended for use following ethmoid or frontal sinus surgery to maintain patency. The implants are intended for use in patients ≥18 years of age. Contraindications include patients with intolerance to mometasone furoate (MF) or a hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females has not been studied. Risks may include pain/pressure, displacement of implant, and possible side effects of intranasal MF. The most common adverse events in clinical studies were sinusitis, headache, epistaxis and bronchitis. For complete prescribing information see IFU at www.intersectent.com. Rx only.

This webpage contains information on investigational devices and drugs. These products are limited by Federal (U.S.) law to investigational use. Intersect ENT makes no claims of safety or effectiveness of these unapproved investigational products. The intent of presenting this information is to convey research and development initiatives underway at Intersect ENT.